We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
3
0 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
1907
No trial phase data available
Completed
2
66.7%
Recruiting
1
33.3%
No approval data available
- A special collection in *Prostate Cancer and Prostatic Diseases* provides a comprehensive assessment of focal therapy (FT) for localized prostate cancer, highlighting mature evidence and emerging technologies. - Pooled data from 49 cohorts show excellent short- to intermediate-term oncological outcomes for HIFU, cryotherapy, and IRE, with overall and cancer-specific survival rates approaching 99%. - Emerging modalities including MRI-guided focused ultrasound, TULSA, focal laser ablation, and histotripsy demonstrate encouraging efficacy with excellent functional preservation, though long-term data remain limited. - Key challenges persist around patient selection, imaging accuracy, standardized surveillance protocols, and the lack of prospective evidence comparing FT oncological efficacy against standard-of-care radical treatments.
